CHINESE JOURNAL OF MEDICINAL GUIDE >
Application and Reflection of Big Data Technology in Pharmacy
Received date: 2025-03-03
Revised date: 2025-10-02
Accepted date: 2025-11-15
Online published: 2025-12-24
In the information age data is constantly being generated and digital transformation has become a national development strategy. China has abundant but not yet fully exploited medical data resources. How to deeply integrate big data technologies with medical fields to empower pharmaceutical services is therefore one of the current research hotspots. Currently, in drug research and development, big data technologies have demonstrated utility in genomic analysis, drug design, and toxicity assessment and prediction. At the clinical level, they can support disease management, optimize medication decisions, and monitor adverse drug reactions. Regarding pharmaceutical management and supervision, these technologies have been applied to digitize bidding and procurement, enhance drug cost control, and "Internet + smart supervision".While big data technologies significantly enhance precision in drug R&D, optimize clinical medication practices, and enable intelligent regulatory oversight, challenges remain, including overcoming technical bottlenecks, refining data governance frameworks, and optimizing talent cultivation mechanisms. Through institutional refinement, advancing technological innovation and practical application, and promoting educational reform, the strategic goal of digital transformation in the pharmaceutical field can be achieved, thereby provide better patient-centered precision pharmaceutical services.This study summarizes real-world applications of big data technologies in the pharmaceutical field and offers insights and prospects to guide and inspire future research and application.
Sha YANG
.
Application and Reflection of Big Data Technology
in Pharmacy
[1] 中国人民共和国工业和信息化部.工业和信息化部关于印发《“十四五”大数据产业发展规划》的通知(工信部规〔2021〕179号)[EB/OL].(2021-11-15)[2025-10-02].https://www.miit.gov.cn/jgsj/ghs/zlygh/art/2022/art_5051b9be5d4740daad48e3b1ad8f728b.html.
[2] 国家数据局.国家数据局等部门关于印发《“数据要素x”三年行动计划(2024—2026年)》的通知(国数政策〔2023〕11号)[EB/OL].(2023-12-31)[2025-10-02].https://www.cac.gov.cn/2024-01/05/c_1706119078060945.htm.
[3] 中共中央办公厅,国务院办公厅.中共中央办公厅 国务院办公厅关于加快公共数据资源开发利用的意见[EB/OL].(2024-09-21)[2025-10-02].https://www.gov.cn/zhengce/202410/content_6978910.htm.
[4] Zhen Z, Hui X, Fang Z. Research on medical big data analysis and disease prediction method based on artificial intelligence[J].Comput Math Methods Med, 2022: 4224287.
[5] 梅宏,杜小勇,金海,等.大数据技术前瞻[J].大数据,2023,9(1):1-20.
[6] 朱德全,吴虑.大数据时代教育评价专业化何以可能:第四范式视角[J].现代远程教育研究,2019,31(6):14-21.
[7] 赵敬丹,李志明.从基于经验到基于数据——大数据时代乡村治理的现代化转型[J].中共中央党校(国家行政学院)学报,2020,24(1):130-135.
[8] 唐金成,宋威辉,李舒淇.论数字经济时代健康保险业的应对策略[J].西南金融,2021,(2):85-96.
[9] 刘永辉,张显,孙鸿雁,等.能源互联网背景下电力市场大数据应用探讨[J].电力系统自动化,2021,45(11):1-10.
[10] Nielsen R. Genomics: In search of rare human variants[J].Nature,2010,467(7319): 1050-1051.
[11] Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci[J].Nat Genet, 2010, 42(6): 508-514.
[12] Ferrero E, Dunham I, Sanseau P. In silico prediction of novel therapeutic targets using gene-disease association data[J]. J Transl Med, 2017,15(1):182.
[13] Pan B, Zhu H, Yang J, et al. From complexity to clarity: development of CHM-FIEFP for predicting effective components in Chinese herbal formulas by using big data[J].Cancer Biol Med, 2024,21(11):1067-1077.
[14] Chvez-Hernndez AL, Jurez-Mercado KE, Saldívar-Gonzlez FI, et al. Towards the De Novo design of HIV-1 protease inhibitors based on natural products[Z].Biomolecules, 2021,11(12):1805.
[15] Lin J, Chen H, Li S, et al. Accurate prediction of potential druggable proteins based on genetic algorithm and Bagging-SVM ensemble classifier[J].Artif Intell Med, 2019,98:35-47.
[16] Tran TTV, Surya Wibowo A, Tayara H, et al. Artificial intelligence in drug toxicity prediction: recent advances, challenges, and future perspectives[J].J Chem Inf Model, 2023,63(9):2628-2643.
[17] Vo AH, Van Vleet TR, Gupta RR, et al. An overview of machine learning and big data for drug toxicity evaluation[J].Chem Res Toxicol, 2020,33(1):20-37.
[18] Zhang L, Ai H, Chen W, et al. CarcinoPred-EL:Novel models for predicting the carcinogenicity of chemicals using molecular fingerprints and ensemble learning methods[J]. Sci Rep, 2017, 7(1):2118.
[19] Russo DP, Strickland J, Karmaus AL, et al. Nonanimal models for acute toxicity evaluations: applying data-driven profiling and read-across[Z], Environ Health Perspect, 2019,127(4):47001.
[20] 吕兰婷,林筑,张延.我国慢性病防控与管理研究的十年综述[J]. 中国卫生事业管理,2020,37(1):32-34,37.
[21] 贾沐晓,杨帆,王晶晶.基于大数据技术探索社区养老医养结合模式[J].智能城市,2020,6(7):12-14.
[22] 孙媛.大数据背景下智慧养老发展路径探究[J].四川劳动保障,2024,(4):119-120.
[23] 肖宁,王家伟.药师将互联网大数据引入慢病管理模式的创新思考[J].中国药房,2016,27(22):3158-3160.
[24] Cao M, Liu Z, Lin Y, et al. A personalized management approach of OHSS: development of a multiphase prediction model and smartphone-based App[J].Front Endocrinol, 2022,13:911225.
[25] Chen X, Yang B, Zhao S, et al. Management for stroke intelligent early warning empowered by big data[J].Comput Electr Eng. 2023,106:108602.
[26] 卞铮,王翊涵,鄢全意,等.大型队列研究数据资源的信息化建设[J]. 中国科学:生命科学,2024,54(6):1021-1028.
[27] 余灿清,李立明.大型队列研究中的数据科学[J]. 中华流行病学杂志,2019,40(1):1-4.
[28] 蒋艳峰,高培培,陈兴栋.大数据时代的大型人群队列[J].生命科学,2023,35(12):1581-1585.
[29] Lin Y, Li J, Xiao H, et al. Automatic literature screening using the PAJO deep-learning model for clinical practice guidelines[J].BMC Med Inform Decis Mak, 2023,23(1):247.
[30] Hong L, Huang S, Cai X, et al. Promoting appropriate medication use by leveraging medical big data[J].Front Digit Health,2024,6:1198904.
[31] 吴纪龙.中医药大数据资源数据仓库构建及处方分析应用研究[D].北京交通大学,2021.
[32] 沈峻,鲁威.基于人工智能的区域处方前置审核系统建设与应用[J]. 中国卫生信息管理杂志,2019,16(4):493-496.
[33] 张清华,金锐,王琨,等.基于循证药学的处方前置审核系统在门诊药房中的实践与探讨[J].中国医院药学杂志,2020,40(4):443-447.
[34] Xu F, Yin J, Zeng S. Practice of prescription review mode based on data mining in hospital[J].Ann Transl Med,2020,8(14):885.
[35] 国务院办公厅关于运用大数据加强对市场主体服务和监管的若干意见[J].中华人民共和国国务院公报,2015,(20):29-37.
[36] 王玲. 试论医疗大数据给药品安全性监测与评价带来的机遇和挑战[J]. 中国药物警戒,2015,12(11):660-664.
[37] 谢吉科,冀召帅,孙坤,等.药品不良反应主动监测及上报管理应用实践[J].中国医院用药评价与分析,2025,25(2):240-243.
[38] 戴梦飞,丁海樱,潘利斌,等.基于FAERS的益生菌制剂相关不良事件信号挖掘与分析[J].中国现代应用药学,2024,41(21):2966-2970.
[39] Chen H, Liu S, Gao S, et al. Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System[J].Sci Rep, 2025,15(1):18063.
[40] 李洁慧,朱晓燕.大数据在控制药品带量采购成本和优化采购流程中的应用[J].甘肃医药,2021,40(12):1127-1129.
[41] 高憬,张元新,李文超.大数据驱动的招标采购数智化体系研究[J]. 招标采购管理,2024,(2):26-29.
[42] 张丽敏,于涛,王孔森.基于集中规模采购大数据分析的采购策略智能制定[J].招标采购管理,2024,(5):32-35.
[43] 许速,谢桦,崔欣,等.基于大数据的病种分值付费的原理与方法[J].中国医疗保险,2020,(9):23-28.
[44] 刘杰荣,罗爱静,黄攀豪,等.基于大数据的单病种住院药品费用合理性筛查实证研究[J]. 医学信息,2018,31(7):10-13.
[45] 郭佳凯.基于数据仓库的电子病历大数据分析[D].中国医科大学,2022.
[46] 唐菀晨,孙浩,由玉伟,等.基于两级数据中心的药品监管数据治理实践与思考[J].中国医药工业杂志,2024,55(7):1037-1043.
[47] 国家药品监督管理局.国家药监局关于发布《药品监管信息化标准体系》的公告(2023年第97号)[EB/OL].(2023-07-31)[2025-10-02].https://www.gov.cn/zhengce/zhengceku/202308/content_6899180.htm.
[48] 李桂桂,张喆,张京梅,等.国家药品智慧监管平台设计与研究[J].中国医药导刊, 2020, 22(10):718722.
[49] Warr WA. Scientific workflow systems:pipeline pilot and KNIME[J].J Comput Aided Mol Des,2012,26(7):801-804.
[50] 庞青云.基于Spotfire的药品检验大数据分析[J].中国药事,2016,30(1):24-31.
[51] 郗昊,冯磊,朱炯,等.基于大数据技术的信息共享平台辅助国家药品抽检工作现状分析及展望[J].中国医药导刊,2019,21(1):50-54.
[52] 刘洋.数字政府建设与药品智慧监管顶层规划的研究与思考[J].中国医药导刊,2023,25(8):773-778.
[53] 范熠明,黄珍妮,朱金涛,等.一种自主配药的智能药箱设计[J].科技与创新,2021,(17):80-81.
/
| 〈 |
|
〉 |